Business Context and Reporting Period
Company: Blade Air Mobility, Inc. (BLDE)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Blade operates an asset-light air mobility platform providing passenger transportation (Short Distance and Jet/Other) and medical logistics (MediMobility Organ Transport). The company is transitioning toward Electric Vertical Aircraft (eVTOL) technology.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Revenue | $70,801 | $67,945 | $125,107 | $119,459 |
| Net Loss | $(3,743) | $(11,326) | $(7,236) | $(15,560) |
| Adjusted EBITDA | $3,190 | $958 | $1,952 | $(2,588) |
| Operating Cash Flow | — | — | $(3,310) | $(7,122) |
| Cash & Equivalents | $58,754 | — | $58,754 | — |
| Short-term Investments | $54,666 | — | $54,666 | — |
| Total Liquidity | $113,420 | — | $113,420 | — |
| Warrant Liability | $2,979 | — | $2,979 | — |
Note: Q2 2024 cash balance data is not explicitly provided in the balance sheet text for the specific date, though 6M 2024 ending cash was $28,366.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 4.2% QoQ and 4.7% YoY (6M). Growth was driven by the Medical segment (+17.6% QoQ, +9.0% YoY 6M) and Jet/Other (+22.3% YoY 6M), offset by a decline in Short Distance passenger revenue (-17.8% QoQ) due to the termination of Canada routes in August 2024 and lower US demand.
- Profitability Improvement: Net loss narrowed significantly, decreasing 67% in Q2 and 53% in the first half of 2025 compared to the prior year. Adjusted EBITDA turned positive, improving from a loss of $2.6M in 6M 2024 to a profit of $2.0M in 6M 2025.
- Cost Management: General and Administrative (G&A) expenses decreased 19.9% QoQ and 11.5% YoY (6M), primarily due to the absence of a $5.8M impairment charge related to Blade Canada in the prior year and reduced intangible amortization.
- Liquidity Position: Cash and cash equivalents increased from $18.4M at year-end 2024 to $58.8M at June 30, 2025, driven by net cash provided by investing activities ($49.1M) from the maturity of held-to-maturity investments.
Outlook, Risks, and Unusual Items
- Strategic Transaction (Passenger Sale): On August 1, 2025, Blade entered an agreement to sell its Passenger business to Joby Aviation. Consideration includes up to $125 million ($90M upfront, $35M earn-out). The transaction is expected to qualify as a discontinued operation.
- Legal Contingencies: The company is defending against the Drulias et al. v. Affeldt class action lawsuit regarding the 2021 merger. Management believes claims are without merit. Legal fees related to this matter are excluded from Adjusted EBITDA.
- Warrant Liability: The company recorded a non-cash gain of $2.8M (6M 2025) due to the decrease in fair value of warrant liabilities, which reduced the reported net loss.
- Seasonality: The Passenger segment historically experiences higher demand in Q2 and Q3. The Medical segment is less seasonal but correlates with organ donor supply.
- Capital Requirements: Management believes current liquidity ($113.4M) is sufficient for operations for at least the next 12 months without additional financing.
Investor Verification Checklist
- Transaction Closing: Verify the status of the Joby Aviation Passenger business sale and the satisfaction of closing conditions.
- Medical Segment Growth: Confirm the sustainability of the 17.6% Q2 revenue growth in the Medical segment and the impact of new contracted customers.
- Warrant Liability Volatility: Monitor the fair value of warrant liabilities, as fluctuations significantly impact reported net income/loss.
- Discontinued Operations: Review future filings to ensure the Passenger business is correctly classified as a discontinued operation post-closing.
- Legal Exposure: Track developments in the Drulias litigation for potential material adverse effects.